8 withdrawn. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Withdrawn 8 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis | Phase 2 | Withdrawn | Stanford University | 2030-12-01 | 2024-12-02 | |
| Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone Naltrexone, Placebo - Atopic Dermatitis, Pruritus | Phase 2 | Withdrawn | University of Minnesota | 2022-12-31 | 2023-04-04 | |
| A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis BX005-A, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Withdrawn | BiomX, Inc. | 2022-05-01 | 2025-08-03 | |
| Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone Naltrexone, Placebo Cream - Atopic Dermatitis, Pruritus | Phase 2 | Withdrawn | University of Minnesota | 2020-10-01 | 2021-04-20 | |
| Moisturizer to Prevent Atopic Dermatitis Cura+ Moisturizing Cream - Dermatitis, Atopic | Phase 2 | Withdrawn | MYOR Ltd. | 2020-06-01 | 2021-01-15 | |
| A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis SAN007 Cream, Placebo - Atopic Dermatitis | Phase 2 | Withdrawn | Santalis Pharmaceuticals, Inc. | 2018-06-01 | 2019-01-17 | |
| A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis Orvepitant, Placebo - Pruritus, Atopic Dermatitis | Phase 2 | Withdrawn | Nerre Therapeutics Ltd. | 2018-05-01 | 2018-05-15 | |
| Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients Moisturizer with each subject's own antimicrobial bacteria - Atopic Dermatitis, Eczema | Phase 2 | Withdrawn | University of California, San Diego | 2015-07-01 | 2020-11-05 |
Pruritus (3) · Dermatitis (2) · Eczema (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Hypersensitivity (8) · Hypersensitivity, Immediate (8) · Immune System Diseases (8) · Skin Diseases (8) · Skin Diseases, Eczematous (8) · Skin Diseases, Genetic (8) · Skin and Connective Tissue Diseases (8) · Dermatitis (6) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Skin Manifestations (3)
Naltrexone (2) · Exercise (1) · Ivermectin (1) · orvepitant (1)
University of Minnesota (2) · BiomX, Inc. (1) · MYOR Ltd. (1) · Nerre Therapeutics Ltd. (1) · Santalis Pharmaceuticals, Inc. (1) · Stanford University (1) · University of California, San Diego (1)
United States (4)
Paul Bigliardi, MD (2) · Elena Fridman, MD (1) · Kavita Sarin, MD, PhD (1) · Richard L Gallo, MD, PhD (1) · Urania Rappo, MD (1)